Tech Company Financing Transactions
QurAlis Funding Round
On 11/20/2018, QurAlis raised $5.5 million in Seed investment from Amgen Ventures, BioInnovation and MP Healthcare Venture Management.
Transaction Overview
Company Name
Announced On
11/20/2018
Transaction Type
Venture Equity
Amount
$5,500,000
Round
Seed
Investors
BioInnovation (Johannes Fruehauf)
Proceeds Purpose
The funding and additional support will allow QurAlis to advance its preclinical research in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) toward the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
700 Main St. North
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
QurAlis is specifically focused on discovering and developing new therapies for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Jonathan Fleming
Chief Executive Officer
Kasper Roet
Chief Scientific Officer
Daniel Elbaum
Founder
Kevin Eggan
Founder
Clifford Woolf
Browse more venture capital transactions:
Prev: 11/19/2018: Visor venture capital transaction
Next: 11/20/2018: ISARA venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs